Looking to know more about the role of the right ventricle in the pathophysiology of tricuspid regurgitation? Don’t miss this video!

You’ll learn how to assess RV function and morphology with advanced imaging, uncover key parameters that predict outcomes, understand how RV remodeling impacts procedural success, and...

Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!

You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...

Explore the latest advancements in aortic valve research during this featured session, showcasing selected abstracts from the upcoming PCR London Valves 2024 conference. Delve into topics ranging from the long-term outcomes of bailout valve-in-valve TAVI, the performance of the Navitor THV in bicuspid aortic valves, novel...

This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.

In this case, a few days after TAVI the heart team has to treat a femoral artery pseudoaneurysm on a 83-year woman. Learn more about their strategy!

Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.